May 5-8, 2024

Event recap: Cencora at ISPOR 2024

Our Cencora teams and global healthcare leaders convened in Atlanta at ISPOR 2024, the leading global conference for Health Economics and Outcomes Research (HEOR).

Learn what our experts covered at the event and download our posters and session presentation materials.

Educational symposia

Staying ahead of the curve: Navigating policy changes and ensuring patient access in the era of IRA and EU HTA

Date: Monday, May 6, 2024
Time: 3:15pm – 4:15pm ET
Moderator: Corey Ford, Cencora
Panelists: Michael Drummond, University of York; Casper Paardekooper, Vintura; Kimberly Westrich, National Pharmaceutical Council

Download presentation slides

Podium session

Unsupported policy information? The Institute for Clinical and Economic Review's unsupported price increase report

Date: Tuesday, May 7, 2024
Time: 2:30pm – 2:45pm ET
Speaker: Jane Ha, Cencora

Read article

Podium session

Decoding payer perspectives: The impact of higher WTP thresholds on ICER’s cost effectiveness determinations

Date: Wednesday, May 8, 2024
Time: 10:00am – 10:15am ET
Speaker: Ben Penley, Cencora

Read article

Did you miss our poster presentations during ISPOR 2024?

Our research covers everything from the most critical challenges facing healthcare to showcasing groundbreaking solutions and the latest advancements in HEOR. We are incredibly proud to contribute to the conversation and share our findings. Browse our list of posters presented at ISPOR 2024, and contact our team if you would like to discuss this research in more detail.

Examining the impact of the Early Access to Medicines Scheme (EAMS) on the National Institute for Health and Care Excellence (NICE) recommendations over the past 4 years | Click here to read poster
A preliminary assessment of ICER’s new HTA methods that support health equity | Click here to read poster
AMNOG benefit assessment in Germany: outcomes from 2011 to 2023 | Click here to read poster
An evaluation of the Rayyan artificial intelligence tool for systematic literature review screening | Click here to read poster | Click here to read the interview with author Joanna Ng
Artificial intelligence for targeted literature review screening within the Rayyan platform | Click here to read poster
Better Late Than Never? Payer Appetite and Vision for a National Value Assessment Body | Click here to read poster
Early patient access to life-saving drugs across Europe—A review of the characteristics and availability of drugs in Early Access Programs in EU4 and the UK | Click here to read poster
Exploring the landscape of genetically modified natural killer cell therapies: a review of clinical trials indexed on ClinicalTrials.gov | Click here to read poster
Lessons from history: Gauging Part D plan access restrictions of protected class drugs as a harbinger for coverage of negotiated drugs | Click here to read poster
Navigating Uncertainty: Trends in ICER’s evidence ratings | Click here to read poster
Prevalence of Plain-Language Summaries (PLSs) in Open Access Patient-Reported Outcome (PRO) Publications | Click here to read poster
Uptake of Early Health Technology Assessment in the United States (US): A Literature Review of Empirical Studies | Click here to read poster
Payer Perspectives on the Use of ICER Evidence Reports Over the Past 24 Months | Click here to read poster

Prepare your patient support program for IRA’s impact

The Part D benefit redesign — as part of the Inflation Reduction Act (IRA) — is almost here. Are you doing enough to prepare your patient support program for it? Watch the video as Corey Ford, Cencora’s VP of Reimbursement and Policy Insights gives a brief overview of what you need to know.

Watch now

Resource Center

What to know about the Inflation Reduction Act (IRA)

Explore our insights and perspectives on the key elements of the new law and tap into our comprehensive understanding of the IRA.

Visit now

Clear the EU Health Technology Assessment (HTA) path

As the European Union takes bold strides towards harmonizing and enhancing its healthcare landscape, the imminent implementation of the Joint Clinical Assessment (JCA) stands as a pivotal moment.

Browse our insights

Catch up on the latest edition of HTA Quarterly

Embarking on the EU HTAR realization journey: Key insights from the first of six implementing acts

Less than one year before the implementation of the European Union Health Technology Assessment Regulation (EU HTAR), industry and national HTA bodies are still missing clarity on the Joint Scientific Consultation (JSC) and Joint Clinical Assessment (JCA) procedures. The first implementing act of JCA has now been published, but does it address the stakeholders’ concerns?

Read article

Benefit-driven pricing: How AMNOG strikes a balance between the financial burden on statutory health insurance and reimbursement of innovative medications in Germany

The German health technology assessment of newly approved drugs aims to relate the declared added benefit with the pricing of pharmaceutical products. How does the outcome of the AMNOG benefit assessment affect the reimbursement negotiations?

Read article

EAMS evidence: A key player in drug value proposition and NICE approval?

The United Kingdom (UK) Medicines and Healthcare Regulatory Agency (MHRA) established the Early Access to Medicines Scheme (EAMS) in 2014 with the intention of providing patients with life-threatening or seriously debilitating conditions access to medicines that have not yet been granted marketing authorisation but address a clear unmet medical need. A decade later, we consider EAMS’ influence on corresponding National Institute of Health and Care Excellence (NICE) recommendations.

Read article

Subscribe today

HTA Quarterly

Catch up on the latest global health technology assessment (HTA) news, gain insights from our experts around evolving HTA priorities, and browse our past issues.

Subscribe now

Additional global market access thought-leadership

Webinar Insights: Navigating the changing landscape of Inflation Reduction Act (IRA) negotiations

Staying ahead of regulatory changes is essential for pharmaceutical companies to thrive in the ever-evolving healthcare landscape. To provide insights into strategic considerations related to the Inflation Reduction Act (IRA), we recently hosted a webinar focusing on strategies to effectively navigate evolving regulatory implementations and increased payer scrutiny.

Navigating new access hurdles in Europe: A conversation with Cencora’s EU HTA Lead

We sat down with our new EU HTA lead, Ruairi O’Donnell, to discuss the importance of the role and what he hopes to achieve in the coming years. In this Q&A interview, we explore key challenges faced by manufacturers navigating the new EU HTA landscape and discuss critical moments manufacturers must seize in order to secure optimized access to patients across Europe.

Start a conversation

Our consultative approach and extensive reach across healthcare give us access to the best insights in the industry- insights we leverage to help commercialization challenges for our partners and patients they serve.

Contact us